Isabel Illa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3442190/publications.pdf

Version: 2024-02-01

81 papers	6,692 citations	101543 36 h-index	64796 79 g-index
86 all docs	86 docs citations	86 times ranked	5483 citing authors

#	Article	IF	Citations
1	Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	30
2	Drugâ€refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Annals of Clinical and Translational Neurology, 2022, 9, 122-131.	3.7	13
3	Predicting Outcome in Guillain-BarrÃ© Syndrome. Neurology, 2022, 98, .	1.1	22
4	Serum neurofilament light chain predicts long-term prognosis in Guillain-BarrÃ© syndrome patients. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 70-77.	1.9	40
5	Clinical characteristics and outcomes of thymomaâ€associated myasthenia gravis. European Journal of Neurology, 2021, 28, 2083-2091.	3.3	39
6	Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain, 2021, 144, 1183-1196.	7.6	46
7	Platelet Derived Growth Factor-AA Correlates With Muscle Function Tests and Quantitative Muscle Magnetic Resonance in Dystrophinopathies. Frontiers in Neurology, 2021, 12, 659922.	2.4	3
8	Isolation of human fibroadipogenic progenitors and satellite cells from frozen muscle biopsies. FASEB Journal, 2021, 35, e21819.	0.5	3
9	Late onset Sandhoff disease presenting with lower motor neuron disease and stuttering. Neuromuscular Disorders, 2021, 31, 769-772.	0.6	6
10	Comment to â€œAutoantibodies to cortactin and agrin in sera of patients with myasthenia gravisâ€. Journal of Neuroimmunology, 2021, 358, 577659.	2.3	0
11	Autoantibody screening in Guillainâ€“BarrÃ© syndrome. Journal of Neuroinflammation, 2021, 18, 251.	7.2	19
12	Myasthenia Gravis Treatment Updates. Current Treatment Options in Neurology, 2020, 22, 1.	1.8	7
13	Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes. BMC Musculoskeletal Disorders, 2020, 21, 784.	1.9	3
14	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurology, The, 2020, 19, 970-971.	10.2	85
15	Genotypeâ€“phenotype correlations in recessive titinopathies. Genetics in Medicine, 2020, 22, 2029-2040.	2.4	35
16	New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. Brain, 2020, 143, 2696-2708.	7.6	45
17	Followâ€up of lateâ€onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1032-1046.	7.3	25
18	Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology, 2020, 94, e1171-e1180.	1.1	88

#	Article	IF	Citations
19	Accuracy of a machine learning muscle MRI-based tool for the diagnosis of muscular dystrophies. Neurology, 2020, 94, e1094-e1102.	1.1	45
20	Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. Journal of the Neurological Sciences, 2020, 412, 116803.	0.6	110
21	Thrombospondin-1 mediates muscle damage in brachio-cervical inflammatory myopathy and systemic sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	12
22	Registro espaÃ±ol de la enfermedad de Pompe: anÃ¡lisis de los primeros 49 pacientes con enfermedad de Pompe del adulto. Medicina ClÃ¡nica, 2020, 154, 80-85.	0.6	9
23	Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT. Molecular Genetics and Metabolism, 2019, 128, 129-136.	1.1	5
24	Identification of serum microRNAs as potential biomarkers in Pompe disease. Annals of Clinical and Translational Neurology, 2019, 6, 1214-1224.	3.7	19
25	Caveats and Pitfalls of SOX1 Autoantibody Testing With a Commercial Line Blot Assay in Paraneoplastic Neurological Investigations. Frontiers in Immunology, 2019, 10, 769.	4.8	26
26	Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy. Scientific Reports, 2019, 9, 6155.	3.3	20
27	Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. PLoS ONE, 2019, 14, e0212647.	2.5	2
28	Longâ€term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve, 2019, 60, 14-24.	2.2	162
29	Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 576-585.	1.9	38
30	Antiâ€“neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo. Journal of Clinical Investigation, 2019, 129, 2222-2236.	8.2	68
31	McLeod syndrome is a new cause of axial muscle weakness. Muscle and Nerve, 2018, 58, E5.	2.2	3
32	Diagnostic utility of cortactin antibodies in myasthenia gravis. Annals of the New York Academy of Sciences, 2018, 1412, 90-94.	3.8	26
33	Regional variation of Guillain-BarrÃ© syndrome. Brain, 2018, 141, 2866-2877.	7.6	190
34	Effect of MAPK Inhibition on the Differentiation of a Rhabdomyosarcoma Cell Line Combined With CRISPR/Cas9 Technology: An In Vitro Model of Human Muscle Diseases. Journal of Neuropathology and Experimental Neurology, 2018, 77, 964-972.	1.7	5
35	A new mutation of the SCGA gene is the cause of a late onset mild phenotype limb girdle muscular dystrophy type 2D with axial involvement. Neuromuscular Disorders, 2018, 28, 633-638.	0.6	15
36	Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study. Scientific Reports, 2018, 8, 10898.	3.3	44

#	Article	IF	Citations
37	JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain, 2018, 141, 1609-1621.	7.6	169
38	Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2018, 45, 220-231.	1.5	4
39	Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy. Cell Death and Disease, 2018, 9, 776.	6.3	36
40	Early diagnosis of amyotrophic lateral sclerosis mimic syndromes: pros and cons of current clinical diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 333-340.	1.7	17
41	Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain, 2017, 140, 1851-1858.	7.6	167
42	Platelet-Derived Growth Factor BB Influences Muscle Regeneration in Duchenne Muscle Dystrophy. American Journal of Pathology, 2017, 187, 1814-1827.	3.8	33
43	ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of autoâ€immunity to nodal components. Journal of the Peripheral Nervous System, 2017, 22, 418-424.	3.1	10
44	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
45	Hypoxia triggers IFN-I production in muscle: Implications in dermatomyositis. Scientific Reports, 2017, 7, 8595.	3.3	30
46	Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Scientific Reports, 2017, 7, 14411.	3.3	62
47	Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nature Reviews Neurology, 2017, 13, 533-547.	10.1	188
48	Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. Journal of Neuroinflammation, 2017, 14, 224.	7.2	50
49	RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis. Arthritis Research and Therapy, 2017, 19, 174.	3.5	34
50	Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. JAMA Neurology, 2016, 73, 1099.	9.0	90
51	Bethlem Myopathy Phenotypes and Follow Up: Description of 8 Patients at the Mildest End of the Spectrum. Journal of Neuromuscular Diseases, 2016, 3, 267-274.	2.6	7
52	Amyotrophic lateral sclerosis: A higher than expected incidence in people over 80 years of age. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 522-527.	1.7	15
53	International consensus guidance for management of myasthenia gravis. Neurology, 2016, 87, 419-425.	1.1	736
54	Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. Journal of Neuroimmunology, 2016, 291, 82-88.	2.3	59

#	Article	IF	Citations
55	Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. Brain, 2016, 139, 1700-1712.	7.6	111
56	Transthyretin-related hereditary amyloid polyneuropathy presenting with large fibre involvement and cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 64-65.	3.0	1
57	Comment to â€œRole of Toll-like receptors and retinoic acid inducible gene I in endogenous production of type I interferon in dermatomyositisâ€. Journal of Neuroimmunology, 2016, 291, 125.	2.3	1
58	Muscle imaging in muscle dystrophies produced by mutations in the EMD and LMNA genes. Neuromuscular Disorders, 2016, 26, 33-40.	0.6	40
59	Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain, 2015, 138, 2847-2858.	7.6	128
60	Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e149.	6.0	205
61	Muscle MRI in muscular dystrophies. Acta Myologica, 2015, 34, 95-108.	1.5	73
62	Severe exacerbation of Andersenâ€“Tawil syndrome secondary to thyrotoxicosis. Journal of Human Genetics, 2014, 59, 465-466.	2.3	3
63	Cortactin autoantibodies in myasthenia gravis. Autoimmunity Reviews, 2014, 13, 1003-1007.	5.8	93
64	Analysis of Serum miRNA Profiles of Myasthenia Gravis Patients. PLoS ONE, 2014, 9, e91927.	2.5	35
65	Dysferlin Regulates Cell Adhesion in Human Monocytes. Journal of Biological Chemistry, 2013, 288, 14147-14157.	3.4	49
66	Role of Thrombospondin 1 in Macrophage Inflammation in Dysferlin Myopathy. Journal of Neuropathology and Experimental Neurology, 2010, 69, 643-653.	1.7	33
67	Sustained Complete Metabolic Remission After Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE).. Blood, 2009, 114, 1181-1181.	1.4	1
68	Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. Journal of Neuroimmunology, 2008, 201-202, 90-94.	2.3	108
69	Expression of Poliovirus Receptor in Human Spinal Cord and Muscle. Annals of the New York Academy of Sciences, 2006, 753, 48-57.	3.8	29
70	Absence of Dysferlin Alters Myogenin Expression and Delays Human Muscle Differentiation â€œin Vitroâ€. Journal of Biological Chemistry, 2006, 281, 17092-17098.	3.4	88
71	IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. Journal of Neurology, 2005, 252, i14-i18.	3.6	25
72	Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology, 2001, 50, 195-201.	5.3	577

#	Article	IF	Citations
73	Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. Annals of Neurology, 2001, 49, 130-134.	5.3	236
74	Cathepsins Are Upregulated by IFN-Î³/STAT1 in Human Muscle Culture: A Possible Active Factor in Dermatomyositis. Journal of Neuropathology and Experimental Neurology, 2001, 60, 847-855.	1.7	49
75	Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. Annals of Neurology, 2001, 49, 130-134.	5.3	4
76	Peripheral Neuropathy Associated with Anti-GM2 Ganglioside Antibodies: Clinical and Immunopathological Studies. Autoimmunity, 2000, 32, 133-144.	2.6	46
77	Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nature Genetics, 1998, 20, 31-36.	21.4	857
78	Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Annals of Neurology, 1998, 44, 976-980.	5.3	140
79	Fulminant Guillain-Barrï¿½ Syndrome with universal inexcitability of peripheral nerves: A clinicopathological study. , 1997, 20, 846-857.		81
80	Acute axonal Guillain-BarrÃ© syndrome with IgG antibodies against motor axons following parenteral gangliosides. Annals of Neurology, 1995, 38, 218-224.	5.3	166
81	Antiganglioside Antibodies in Patients with Acute Polio and Post-Polio Syndrome. Annals of the New York Academy of Sciences, 1995, 753, 374-377.	3.8	11